Hematologic response according to chemotherapy regimen
| Regimen . | No. of patients . | Hematologic response (%) . |
|---|---|---|
| Chlorambucil | 22 | 6 (27) |
| VAD | 9 | 4 (44)* |
| IDM | 8 | 1 (12) |
| Oral melphalan | 6 | 1 (16) |
| Oral cyclophosphamide | 6 | 0 (0) |
| CVP | 3 | 1 (33) |
| R-CVP | 2 | 1 (50) |
| CHOP | 2 | 2 (100)* |
| CTD | 3 | 1 (33) |
| FCR | 3 | 2 (66)* |
| Fludarabine or cladribine | 2 | 2 (100) |
| Others† | 11 | 3 (27)* |
| Regimen . | No. of patients . | Hematologic response (%) . |
|---|---|---|
| Chlorambucil | 22 | 6 (27) |
| VAD | 9 | 4 (44)* |
| IDM | 8 | 1 (12) |
| Oral melphalan | 6 | 1 (16) |
| Oral cyclophosphamide | 6 | 0 (0) |
| CVP | 3 | 1 (33) |
| R-CVP | 2 | 1 (50) |
| CHOP | 2 | 2 (100)* |
| CTD | 3 | 1 (33) |
| FCR | 3 | 2 (66)* |
| Fludarabine or cladribine | 2 | 2 (100) |
| Others† | 11 | 3 (27)* |
VAD indicates vincristine-adriamycin-dexamethasone; IDM, intravenous melphalan (25mg/m2); CVP, cyclophosphamide-vincristine-prednisone; R-CVP, rituximab-cycophosphamide-vincristine-prednisone; CHOP, cyclophosphamide-doxorubicin-vincristine-prednisone; CTD, cyclophosphamide-thalidomide-dexamethasone; and FCR, fludarabine-cyclophopshamide-rituximab.
Organ response; each symbol denoted 1 patient.
Others indicates R-CHOP, single-agent rituximab, intravenous cyclophosphamide, thalidomide-dexamethasone, lomustine-idarubicin-dexamethasone, single-agent dexamethasone, fludarabine-cyclophosphamide, idarubicin-dexamethasone, and stem cell transplantation in 1 patient each.